Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Our last article on Milestone Pharmaceuticals Inc. (NASDAQ: MIST ), which saw tremendous interest from the community, discussed the solid clinical data set and market potential of Milestone's intranasally administered calcium channel blocker, etripamil. Milestone experienced a major setback, receivingWe target small and microcap biopharmaceuticals companies where our advantage is greatest and mispricing is most intense. These young, often clinical stage companies have little to no institutional attention. A ...